Synergy CHC Corp. SNYR
requires, for purposes of this section, the terms "we," "us," "the Company" or "Synergy"
refer to Synergy CHC Corp.
health care, beauty, and lifestyle products. Our current brand portfolio consists of two marquee brands, FOCUSfactor, a clinically-tested brain
health supplement (this study was performed independently and is not related to any U.S. Food and Drug Administration ("FDA")
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by geography
- United States
- Canada
- Mexico
- Other
| Region | FY2025 |
|---|---|
| United States | $27.3M |
| Canada | $2.4M |
| Mexico | $623.7K |
| Other | $20.7K |
As the company reported it, from the “Segments - Schedule of Net sales Attributed to Customers in the United States and Foreign Countries (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.
Revenue by segment
- Nutraceuticals
- Beverages
- Other
| Segment | FY2025 | FY2024 |
|---|---|---|
| Nutraceuticals | $29.7M | $33.4M |
| Beverages | $631.3K | $1.4M |
| Other | $18.0K | $16.9K |
As the company reported it, from the “Segments - Schedule of Net Sales Attributed to Customers Product Group (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Segments are the filer's own reporting structure, which is a decision about how it runs itself rather than a standard taxonomy: two companies in the same industry routinely divide themselves along different lines, so these are worth reading down a single company rather than across two. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.4M | $34.8M | $42.8M | — | $29.4M | $33.8M | $35.6M | $34.8M | $13.5M | $9.2K |
| Cost of revenue | $10.1M | $11.2M | $10.7M | — | $9.1M | $11.0M | $9.8M | $10.2M | $5.3M | $5.6K |
| Gross profit | $20.3M | $23.6M | $32.1M | — | $20.2M | $22.8M | $25.8M | $24.6M | $8.1M | $3.5K |
| SG&A | $8.8M | $4.7M | $6.1M | — | $5.5M | $7.2M | $8.4M | $8.0M | $3.4M | $961.6K |
| Total operating expenses | $28.8M | $17.8M | $21.3M | — | $28.2M | $27.7M | $24.0M | $21.7M | $7.7M | $961.6K |
| Operating income | -$8.5M | $5.8M | $10.8M | — | -$8.0M | -$4.9M | $1.8M | $2.9M | $486.0K | -$958.1K |
| Interest expense | $5.9M | $4.1M | $1.7M | — | — | $1.1M | $1.0M | $1.6M | $958.7K | $2.0K |
| Pre-tax income | -$12.2M | $2.2M | $6.6M | — | -$9.1M | -$6.4M | $815.6K | $148.2K | -$7.1M | -$960.1K |
| Income tax | $117.5K | $102.1K | $235.0K | — | $131.5K | $247.7K | $316.0K | $944.4K | $389.9K | $0 |
| Net income | -$12.3M | $2.1M | $6.3M | — | -$9.2M | -$6.2M | $499.6K | -$796.2K | -$7.5M | -$960.1K |
| EPS, basic | -1.27 | 0.28 | 0.86 | — | -0.10 | -0.07 | 0.01 | — | — | — |
| EPS, diluted | -1.27 | 0.28 | 0.86 | — | -0.10 | -0.07 | 0.01 | -0.01 | -0.11 | -0.01 |
| Shares, diluted (wtd. avg.) | 9.7M | 7.6M | 7.4M | — | 89.9M | 89.9M | 89.2M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.6M | $687.9K | $732.5K | $2.5M | $1.2M | $459.7K | $2.0M | $2.5M | $3.6M | $338 |
| Receivables | $3.2M | $5.3M | $2.1M | — | $1.4M | $4.5M | $4.3M | $2.2M | $4.0M | $2.9K |
| Inventory | $3.7M | $1.7M | $3.7M | — | $1.9M | $2.7M | $2.8M | $1.1M | $686.7K | $26.1K |
| Total current assets | $10.0M | $16.1M | $11.8M | — | $5.0M | $8.9M | $10.4M | $7.3M | $9.3M | $55.4K |
| Property, plant and equipment | — | — | — | — | $135.9K | $269.8K | $293.2K | $257.4K | $12.0K | — |
| Goodwill | — | — | — | — | — | $7.8M | $7.8M | $7.8M | $11.5M | — |
| Other intangibles | $150.0K | $283.3K | $416.7K | — | $7.6K | $3.0M | $5.5M | $5.1M | $5.9M | — |
| Total assets | $10.2M | $16.3M | $12.2M | — | $5.2M | $20.0M | $24.0M | $20.5M | $26.8M | $55.4K |
| Accounts payable | $6.4M | $5.2M | $11.7M | — | $4.7M | $8.4M | $4.3M | $4.6M | $5.0M | $74.6K |
| Short-term debt | — | $4.0M | $2.1M | — | — | $28.2K | $0 | $750.0K | $750.0K | $6.4K |
| Total current liabilities | $8.2M | $17.2M | $14.0M | — | $10.1M | $10.4M | $7.1M | $12.2M | $15.4M | $181.0K |
| Long-term debt | $25.1M | $7.5M | $13.1M | — | — | — | — | — | — | — |
| Total liabilities | $33.3M | $33.0M | $39.5M | — | $10.4M | $16.0M | $14.6M | $13.4M | $21.3M | $181.0K |
| Retained earnings | -$56.4M | -$44.1M | -$46.2M | — | -$24.2M | -$15.0M | -$8.9M | -$9.4M | -$8.6M | -$1.0M |
| Total equity | -$23.1M | -$16.6M | -$27.3M | -$33.5M | -$5.2M | $4.0M | $9.4M | $7.1M | $5.4M | -$125.7K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.6M | -$4.8M | $421.7K | — | $2.9M | $1.3M | -$831.1K | $6.0M | -$644.3K | -$489.2K |
| Depreciation and amortisation | — | $133.3K | $33.3K | — | $133.9K | $152.5K | $108.1K | $44.5K | $1.5K | $0 |
| Stock-based compensation | $136.2K | — | — | — | $201.2K | $441.0K | $1.5M | $2.2M | $551.7K | $322.2K |
| Capital expenditure | — | — | — | — | — | $129.1K | $153.0K | $302.2K | $7.8K | — |
| Investing cash flow | — | — | — | — | — | -$198.0K | -$1.9M | -$2.3M | -$4.4M | — |
| Financing cash flow | $4.7M | $4.8M | -$2.1M | — | -$2.0M | -$2.9M | $2.3M | -$4.8M | $8.7M | $486.3K |
| Dividends paid | — | — | — | — | — | — | — | — | $1.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-050246.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.2K | $13.5M | $34.8M | $35.6M | $33.8M | $29.4M | — | $42.8M | $34.8M | $30.4M |
| Gross profit | $3.5K | $8.1M | $24.6M | $25.8M | $22.8M | $20.2M | — | $32.1M | $23.6M | $20.3M |
| Net income | -$960.1K | -$7.5M | -$796.2K | $499.6K | -$6.2M | -$9.2M | — | $6.3M | $2.1M | -$12.3M |
Recent filings and events
- Debt acceleration or default Something has triggered a lender's right to demand early repayment - usually a covenant breach. Item 2.04
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Debt acceleration or default Item 2.04
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Delisting notice Item 3.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2833
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| DFTX | Definium Therapeutics, Inc. | $4.79B | — | — |
| TRLV | Trulieve Cannabis Corp. | $2.01B | — | -0.4% |
| CRON | Cronos Group Inc. | $1.23B | — | 24.6% |
| TLRY | Tilray Brands, Inc. | $382.7M | — | 11.5% |
| CGC | Canopy Growth Corp | $285.9M | — | — |
| USNA | USANA HEALTH SCIENCES INC | $257.9M | 24.1x | 8.3% |
| NAGE | Niagen Bioscience, Inc. | $192.3M | 12.2x | 29.9% |
| FTLF | FITLIFE BRANDS, INC. | $78.4M | 13.3x | 26.4% |